 Shares of Accuray NASDAQ:ARAY rose 1.66 in after-market trading after the company reported Q4 results.Quarterly Results Earnings per share rose 100.00 year over year to 0.00, which beat the estimate of 0.02.Revenue of 94,977,000 decreased by 19.11 from the same period last year, which beat the estimate of 91,560,000.Looking Ahead Accuray hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 13, 2020View more earnings on ARAYTime: 04:30 PMET Webcast URL: 52-week high: 4.6852-week low: 1.33Price action over last quarter: Up 12.71Company Profile Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The companys technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis.See more from Benzinga Earnings Scheduled For August 13, 2020 Accurays Earnings OutlookC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 